Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1 - Mapping the site of binding

Department of Life Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84105, Israel.
Journal of Biological Chemistry (Impact Factor: 4.6). 06/2008; 283(19):13482-90. DOI: 10.1074/jbc.M708216200
Source: PubMed

ABSTRACT In brain and tumor cells, the hexokinase isoforms HK-I and HK-II bind to the voltage-dependent anion channel (VDAC) in the outer mitochondrial membrane. We have previously shown that HK-I decreases murine VDAC1 (mVDAC1) channel conductance, inhibits cytochrome c release, and protects against apoptotic cell death. Now, we define mVDAC1 residues, found in two cytoplasmic domains, involved in the interaction with HK-I. Protection against cell death by HK-I, as induced by overexpression of native or mutated mVDAC1, served to identify the mVDAC1 amino acids required for interaction with HK-I. HK-I binding to mVDAC1 either in isolated mitochondria or reconstituted in a bilayer was inhibited upon mutation of specific VDAC1 residues. HK-I anti-apoptotic activity was also diminished upon mutation of these amino acids. HK-I-mediated inhibition of cytochrome c release induced by staurosporine was also diminished in cells expressing VDAC1 mutants. Our results thus offer new insights into the mechanism by which HK-I promotes tumor cell survival via inhibition of cytochrome c release through HK-I binding to VDAC1. These results, moreover, point to VDAC1 as a key player in mitochondrially mediated apoptosis and implicate an HK-I-VDAC1 interaction in the regulation of apoptosis. Finally, these findings suggest that interference with the binding of HK-I to mitochondria by VDAC1-derived peptides may offer a novel strategy by which to potentiate the efficacy of conventional chemotherapeutic agents.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: VDAC1 is a multi-functional mitochondrial protein regulating cell life and death•Silencing VDAC1 over-expressed in cancer inhibits cell growth in vivo and in vitro•VDAC1 activities are modulated by associated proteins•A novel mechanism for VDAC1-mediated release of apoptotic proteins is presented•VDAC1-based strategies are proposed for cancer therapeutic applications
    Biochimica et Biophysica Acta (BBA) - Biomembranes 11/2014; DOI:10.1016/j.bbamem.2014.10.040 · 3.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The characterization of the antiproliferative potential of the ketoimine platinum complex trans[PtCl2{RC(=O)N=CN-(H)C(Me)(2)-CH2CH2}(2)] (R = CH2CO2Me) is reported. It showed a higher cytotoxicity against HCT116 and HepG2 cancer cells (IC50 values of 22.74 +/- 0.04 mu M and 22.08 +/- 0.08 mu M, respectively) compared to fibroblasts and a non-tumorigenic cell line. It was also observed a moderate ability of the complex to induce apoptosis in HCT116 cells, as observed by fluorescence microscopy and flow cytometry. The observed antiproliferative activities of the complex are mostly due to delay in the cell cycle progression. In vitro DNA interaction studies revealed a DNA affinity constant of 6.67 x 10(5) M-1, suggesting a high affinity to DNA, by comparison to the value obtained for doxorubicin. A decrease in the electrophoretic mobility of the supercoiled plasmid DNA (pDNA) suggested the formation of complex-DNA adducts. However, the complex did not exhibit relevant genotoxicity in V79 cells. Proteomic assays demonstrated that the ketoimine Pt(II) complex promotes an overexpression of two negative cell cycle regulators, PA2G4 and 14-3-3 sigma, and PHB, and a decrease in expression of VDAC1 and HSP90B, probably associated with the antiproliferative potential. The ketoimine Pt(II) complex is able to trigger an overexpression of cytoskeleton-associated proteins in agreement with its ability to maintain cell structure, and an overexpression of oxidative stress enzymes, coping with the induction of ROS formation, observed by in vitro EMSA assays. In conclusion, the ketoimine Pt(II) complex is an antiproliferative agent with potential to be used against cancer cells.
    Inorganica Chimica Acta 11/2014; 423:156-167. DOI:10.1016/j.ica.2014.07.067 · 2.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondria require cholesterol for biogenesis and membrane maintenance, and for the synthesis of steroids, oxysterols and hepatic bile acids. Multiple pathways mediate the transport of cholesterol from different subcellular pools to mitochondria. In steroidogenic cells, the steroidogenic acute regulatory protein (StAR) interacts with a mitochondrial protein complex to mediate cholesterol delivery to the inner mitochondrial membrane for conversion to pregnenolone. In non-steroidogenic cells, several members of a protein family defined by the presence of a StAR-related lipid transfer (START) domain play key roles in the delivery of cholesterol to mitochondrial membranes. Subdomains of the endoplasmic reticulum (ER), termed mitochondria-associated ER membranes (MAM), form membrane contact sites with mitochondria and may contribute to the transport of ER cholesterol to mitochondria, either independently or in conjunction with lipid-transfer proteins. Model systems of mitochondria enriched with cholesterol in vitro and mitochondria isolated from cells with (patho)physiological mitochondrial cholesterol accumulation clearly demonstrate that mitochondrial cholesterol levels affect mitochondrial function. Increased mitochondrial cholesterol levels have been observed in several diseases, including cancer, ischemia, steatohepatitis and neurodegenerative diseases, and influence disease pathology. Hence, a deeper understanding of the mechanisms maintaining mitochondrial cholesterol homeostasis may reveal additional targets for therapeutic intervention. Here we give a brief overview of mitochondrial cholesterol import in steroidogenic cells, and then focus on cholesterol trafficking pathways that deliver cholesterol to mitochondrial membranes in non-steroidogenic cells. We also briefly discuss the consequences of increased mitochondrial cholesterol levels on mitochondrial function and their potential role in disease pathology.
    Journal of Bioenergetics 11/2014; DOI:10.1007/s10863-014-9592-6 · 2.71 Impact Factor